Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259384 | 0.66 | SIGMAR1 (0.52) | SIGMAR1LMNACYP1A2CYP2C19OPRL1 | |
| SCHEMBL22175918 | 0.64 | SIGMAR1 (0.50) | SIGMAR1LMNA | |
| SCHEMBL20559035 | 0.64 | LMNA (0.37) | NAMPTLMNAGAA | |
| SCHEMBL1038115 | 0.63 | SIGMAR1 (0.47) | SIGMAR1NAMPTOPRL1 | |
| SCHEMBL6277987 | 0.62 | MAOB (0.34) | SIGMAR1 | |
| SCHEMBL10869311 | 0.62 | POLM (0.44) | PPARGKMT2A | |
| SCHEMBL10868978 | 0.62 | POLM (0.44) | PPARGKMT2A | |
| SCHEMBL29123516 | 0.62 | MEN1 (0.44) | CYP2C9CYP2C19KMT2A | |
| SCHEMBL11496823 | 0.62 | SIGMAR1 (0.45) | SIGMAR1 | |
| SCHEMBL12050765 | 0.62 | LMNA (0.47) | SIGMAR1NAMPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741962-B2 | Process for preparation of Rasagiline and salts thereof | USV LIMITED (IN) | 2014-06-03 | — | — | US | disclosed |
| EP-2364967-A2 | Process for preparation of rasagiline and salts thereof | USV Limited (IN) | 2011-09-14 | — | — | EP | disclosed |
| US-20110155626-A1 | PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF | USV LIMITED (IN) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110155626-A1 | PROCESS FOR PREPARATION OF RASAGILINE AND SALTS THEREOF | RAB27A, RAB35, RAB7A | SIGMAR1 3861/4885NAMPT 1196/4885LMNA 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.